Cargando…

Multivalent γ‐PGA‐Exendin‐4 Conjugates to Target Pancreatic β‐Cells

Targeting of glucagon‐like peptide 1 receptor (GLP‐1R), expressed on the surface of pancreatic β‐cells, is of great interest for the development of advanced therapies for diabetes and diagnostics for insulinoma. We report the conjugation of exendin‐4 (Ex‐4), an approved drug to treat type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Lorenzo, Kerekes, Krisztina, Kovács‐Kocsi, Judit, Körhegyi, Zoltán, Bodnár, Magdolna, Fazekas, Erika, Prépost, Eszter, Pignatelli, Cataldo, Caneva, Enrico, Nicotra, Francesco, Russo, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542156/
https://www.ncbi.nlm.nih.gov/pubmed/35762648
http://dx.doi.org/10.1002/cbic.202200196
Descripción
Sumario:Targeting of glucagon‐like peptide 1 receptor (GLP‐1R), expressed on the surface of pancreatic β‐cells, is of great interest for the development of advanced therapies for diabetes and diagnostics for insulinoma. We report the conjugation of exendin‐4 (Ex‐4), an approved drug to treat type 2 diabetes, to poly‐γ‐glutamic acid (γ‐PGA) to obtain more stable and effective GLP‐1R ligands. Exendin‐4 modified at Lysine‐27 with PEG4‐maleimide was conjugated to γ‐PGA functionalized with furan, in different molar ratios, exploiting a chemoselective Diels‐Alder cycloaddition. The γ‐PGA presenting the highest number of conjugated Ex‐4 molecules (average 120 per polymeric chain) showed a double affinity towards GLP‐1R with respect to exendin per se, paving the way to improved therapeutic and diagnostic applications.